Therapicon Srl
Main menu:
Sialomimetic compounds (antivirals)
In view of the gained experience, another research project has been designed to yield additional neuraminic acid analogues with enhanced neuraminidase inhibitory effect. Neuraminidase pays an essential role in the viral adhesion of virus, bacteria and protozoa to the host cells and it is essential for their replication. Neuraminidase inhibition prevents the progressive multiplication of those infecting pathogens.
The multifunctional compounds resulting from the condensation of modified neuraminic acid and moieties of known neuraminidase inhibitors (oseltamivir, zanamivir, peramivir, laninamivir) while potentiating the inhibition it is believed to delay the development of drug peramivir In vitro tests suitably confirmed that the new compounds elicit remarkable inhibitory effect in several Influenza Type A and Type B virus strains, including those resistant rimantadine and oseltamivir. Furthers pharmacological and non clinical studies have been scheduled during the next months to assess their inhibitory effect in influenza virus animal models.
Therapicon® is a registered trade-mark in Italy and at OMPI (WIPO)-Geneva